Table 2 Correlation of clinicopathological characteristics and NLR(or PLR) levels in rectal cancer

Age(y)

0.418

0.796

 ≥65

19(50.0%)

61(42.7%)

67(43.8%)

13(46.4%)

 <65

19(50.0%)

82(57.3%)

86(56.2%)

15(53.6%)

Sex

0.826

 Male

22(57.9%)

91(63.6%)

0.320

95(62.1%)

18(64.3%)

 Female

16(41.1%)

52(36.4%)

58(37.9%)

10(35.7%)

Location

(cm)

0.577

0.888

 ≥ 5

29(76.3%)

115(80.4%)

122(79.7%)

22(78.6%)

 < 5

9(23.7%)

28(19.6%)

31(20.3%)

6(21.4%)

TNM

0.515

0.003*c

 I

6(15.8%)

32(22.4%)

29(19.0%)

9(32.1%)

 II

11(28.9%)

46(32.2%)

43(28.1%)

14(50%)

 III

21(55.3%)

65(45.4%)

81(52.9%)

5(17.9%)

PNI

0.442

0.004*

 Negative

17(44.7%)

74(51.7%)

70(45.8%)

21(75.0%)

 Positive

21(55.3%)

69(48.3%)

83(54.2%)

7(25.0%)

LVI

0.172

0.025*

 Negative

16(42.1%)

78(54.5%)

74(48.4%)

20(71.4%)

 Positive

22(57.9%)

65(45.5%)

79(51.6%)

8(28.6%)

TDs

0.730_a

0.028*_a

 Negative

34(89.5%)

125(87.4%)

131(85.6%)

28(100%)

 Positive

4(10.5%)

18(12.6%)

22(14.4%)

0(0%)

Lymph nodes metastasis

0.361

< 0.001*

 No

17(44.7%)

78(54.5%)

72(47.1%)

23(82.1%)

 Yes

21(55.3%)

65(45.5%)

81(52.9%)

5(17.9%)

TLN(median, IQR)

19.5

(15.0−24.7)

18

(14.0–22.0)

0.227_b

18.0(15.0–22.0)

18.5(14.0–20.0)

0.283_b

CEA(ng/ml)

0.853

0.005*

 ≥5

14(36.8%)

56(39.2%)

66(43.1%)

4(14.3%)

 <5

24(63.2%)

87(60.8%)

87(56.9%)

24(85.7%)

CA199

(ng/ml)

0.823

0.800

 ≥27

8(21.1%)

28(19.6%)

30(19.6%)

6(21.4%)

 <27

30(78.9%)

115(80.4%)

123(80.4%)

22(78.6%)